TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Bio Vitos Pharma AB
Closing information (x1000 EUR)
| Closing information | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Turnover |
270
|
119
|
110 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-1,160
|
-1,339
|
-1,364 |
| EBITDA |
-316
|
-699
|
-737 |
| Total assets |
3,057
|
2,377
|
3,471 |
| Current assets |
461
|
469
|
1,085 |
| Current liabilities |
91
|
137
|
192 |
| Equity capital |
2,966
|
2,240
|
3,279 |
| - share capital |
386
|
278
|
170 |
| Employees (average) |
1
|
5
|
6 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Solvency |
97.0%
|
94.2%
|
94.5% |
| Turnover per employee |
270
|
24
|
18 |
| Profit as a percentage of turnover |
-429.6%
|
-1125.2%
|
-1240.0% |
| Return on assets (ROA) |
-37.9%
|
-56.3%
|
-39.3% |
| Current ratio |
506.6%
|
342.3%
|
565.1% |
| Return on equity (ROE) |
-39.1%
|
-59.8%
|
-41.6% |
| Change turnover | |||
| Change turnover % |
18%
|
265% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
-17%
|
20% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.